DossierENTITY

Phase 2b study

Coverage of Phase 2b study in the Nexus archive.

Earliest in view: Jun 1 · 16:59 UTCMost recent: Jun 1 · 16:59 UTC

Co-mentioned in this coverage

Recent coverage

HEALTHJun 1 · 16:59 UTCTHE HILL
Personalized mRNA vaccine shows promise in reducing melanoma return: Research
A personalized mRNA vaccine developed by Moderna and Merck shows promise in reducing the recurrence of melanoma, the deadliest form of skin cancer, according to a five-year follow-up of a Phase 2b study.